- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01865136
Post-abortion Care and Contraceptive Counselling by Midwives or Physicians
Post-abortion Care and Contraceptive Counselling by Midwives or Physicians - a Randomized Controlled Trial in Kisumu, Western Kenya
The aim of this project is to study the safety, efficacy and effectiveness of medical treatment of incomplete abortion provided to women by physicians or midwives in Kisumu, Kenya.
In Kenya, Post Abortion Care (PAC), provided by physicians, nurse-midwives and clinical officers, has been integrated at private reproductive health facilities since 1998. Misoprostol as treatment of incomplete abortion was launched I Nyanza Province in April, 2012. The involvement of midwives in medical (Misoprostol) treatment of incomplete abortion has, however, not been systematically evaluated. There is a need to determine whether midwives and physician can perform medical treatment of incomplete abortion equally safe and effective in Kenya. The results will thus provide evidence-based information that can contribute to the development of strategies to increase women's access to Post Abortion Care in Kenya as well as in other low-income contexts.
Study Overview
Detailed Description
The project will take place at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) and Kisumu East District Hospital (KEDH), in Kisumu County of Nyanza Province in Western Kenya. The project will be implemented within the Department of Obstetrics and Gynaecology at the two facilities. Altogether the two facilities admit around 60 women per month with incomplete abortion. Midwives and physicians included in the project will undergo a standardized training prior to the study. This will include basic knowledge on treatment of incomplete abortion and post abortion contraceptive counselling as well as interview technique. The training will be both theoretical and practical and on-going during the project in order to cover all / new staff.
The sample size has been calculated with the objective of showing two-sided equivalence, assuming that the overall complication rate could be as high as 4-5 percent and would apply to both types of providers. To demonstrate two-sided equivalence within a margin of 4-5 percent with 80% power and using a 95% CI (α=0.05), about 816 women would need to be recruited. In addition, about 10 percent could be expected lost to follow up and will be adjusted for. Thus, a total of 880 women will be recruited. The randomization will be conducted in blocks of 8 and will vary randomly. A computer random number generator will be used to generate a list of codes from 1 to 880 and each code is linked to one of the two groups - A= PAC care and misoprostol by midwife and B= PAC care and misoprostol by physician. The list will be used while sequentially numbered, opaque, sealed envelopes will be prepared by the research team. Each envelope contains a study protocol for the individual woman. At the time of allocation, the research assistant at the clinic will pick the envelope with the lowest number, write the participant's name and personal registration number on it, and then open it. Process evaluation will be conducted by intermittent check-ups in order to assure that the intervention procedures are performed correctly and that they follow the protocol. The check-ups will be made by a researcher and include both a review of the completed protocols and repetition and education of the physicians and midwives involved in the study.
All eligible women who consent to participation will undergo a clinical assessment by the provider they have been randomized to. The clinical assessment includes (i) medical history taking , Last Menstrual Period (LMP), Obstetric and Gynaecological history, contraceptive history, symptoms) (ii) General physical examination (pulse, blood pressure and temperature); (iii) Pelvic examination that include examination of size of the uterus (External genitalia, speculum examination, Bimanual examination). Before discharge all women will be given detailed information regarding bleeding and pain expected following treatment as well as abnormal symptoms (fever, and foul smelling vaginal discharge) and the importance of seeking care if such symptoms occur. All women will be followed-up after 7 - 10 days.
All analyses will be by Intention to Treat (ITT). Background characteristics for the two study groups and categorical outcomes will be presented using descriptive statistics. Differences between groups will be analysed using relative risks (95% CI). P-values equal to or lower than 0.05 will be considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kisumu, Kenya
- Jaramogi Oginga Odinga Teaching and Referral Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women presenting with vaginal bleeding in the first trimester of pregnancy and diagnosed to have incomplete abortion
Exclusion Criteria:
- Women with unstable hemodynamic status and shock, signs of sepsis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Medical Post Abortion Care by Midwife
Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
|
Women with incomplete abortion is diagnosed and treated with misoprostol
|
|
No Intervention: Medical Post Abortion Care by physician
Women with incomplete abortion is diagnosed and treated with misoprostol by physician
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete abortion requiring no further medical or surgical intervention.
Time Frame: 7-10 days after intervention
|
The clinical assessments of the main outcome are: (i) Physical examination (pulse, blood pressure and temperature); (ii) Pelvic examination that include examination of size of the uterus (External genitalia, speculum examination, Bimanual examination).
|
7-10 days after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bleeding
Time Frame: 7-10 days after intervention
|
Measurements of pain is conducted using symptom diary card used by women to assess daily bleeding and pain.
The intensity of bleeding will be self-reported by the women in relation to normal menstrual bleeding (categorised 1=much less than up to 5= much heavier than.
|
7-10 days after intervention
|
|
Pain
Time Frame: 7-10 days after intervention
|
Measurements of pain is conducted using symptom diary card used by women to assess daily bleeding and pain.
Pain reported using visual analogue scale (VAS) before any use of analgesia.
|
7-10 days after intervention
|
|
Acceptability
Time Frame: 7-10 days
|
Standardized questionnaires will be used to collect information about women's acceptability and experiences of the treatment and time spent on travelling and on clinical visits following treatment.
|
7-10 days
|
|
Un-scheduled visit
Time Frame: 7-10 days
|
Standardized questionnaires will be used to collect information about time spent on travelling and on clinical visits following treatment.
|
7-10 days
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Contraceptive uptake
Time Frame: 7-10 days
|
7-10 days
|
|
Contraceptive uptake
Time Frame: 3 month
|
3 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Monica Oguttu, Director, KMET
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PAC 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Kafrelsheikh UniversityNot yet recruitingEctopic PregnancyEgypt
-
Meir Medical CenterRecruiting
-
Bagcilar Training and Research HospitalRecruitingEctopic PregnancyTurkey (Türkiye)
-
MELISA Institute Genomics & Proteomics Research...RecruitingHealthy | Pregnancy | Early Pregnancy | Early Pregnancy Loss | ChildbirthChile
-
Turku University HospitalUniversity of TurkuCompleted
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
Clinical Trials on Medical Post Abortion Care
-
University of California, San FranciscoInnovations for Poverty Action; Marie Stopes InternationalCompletedReproductive HealthKenya
-
Gynuity Health ProjectsCompleted
-
Gynuity Health ProjectsScientific Research Institute of Obstetrics and GynecologyCompletedPregnancy RelatedAzerbaijan
-
Reproductive Health Training Center of the Republic...Grand Challenges Canada; Gynuity Health ProjectsCompletedPregnancyMoldova, Republic of
-
Gynuity Health ProjectsCompleted
-
Gynuity Health ProjectsCharitable Foundation Women Health and Family Planning, Ukraine; Women's Wellness...CompletedPregnancyUkraine, Uzbekistan
-
Gynuity Health ProjectsCompleted
-
IpasUniversity of Health Science, Phnom Penh, CambodiaCompletedMisoprostol | Induced Abortion | First Trimester Abortion | MifepristoneCambodia, Ghana
-
Mansoura UniversityNot yet recruitingAbortion | Maternity | PracticeEgypt
-
Gynuity Health ProjectsCompletedComplete AbortionVietnam, Tunisia